S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
US Dollar Replaced By "Biden Bucks"? (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast (Ad)
NASDAQ:LXRX

Lexicon Pharmaceuticals - LXRX Stock Forecast, Price & News

$3.17
+0.41 (+14.86%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.79
$3.27
50-Day Range
$1.31
$3.27
52-Week Range
$1.31
$6.33
Volume
3.26 million shs
Average Volume
1.03 million shs
Market Capitalization
$582.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

Lexicon Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
373.2% Upside
$15.00 Price Target
Short Interest
Healthy
4.45% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.19mentions of Lexicon Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$40.43 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

328th out of 1,117 stocks

Pharmaceutical Preparations Industry

159th out of 550 stocks

LXRX stock logo

About Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Citigroup raised their price objective on Lexicon Pharmaceuticals from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Friday, July 1st. Piper Sandler began coverage on Lexicon Pharmaceuticals in a report on Friday. They issued an "overweight" rating and a $10.00 price objective for the company.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX Stock opened at $3.17 on Friday. The firm has a market cap of $582.09 million, a price-to-earnings ratio of -4.82 and a beta of 1.50. Lexicon Pharmaceuticals has a 52-week low of $1.31 and a 52-week high of $6.33. The company has a quick ratio of 3.85, a current ratio of 3.85 and a debt-to-equity ratio of 0.33. The company's 50 day moving average is $2.35 and its 200 day moving average is $2.30.

Insider Buying and Selling at Lexicon Pharmaceuticals

In related news, Director International S.C.A. Artal purchased 16,173,800 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, August 1st. The stock was purchased at an average cost of $2.50 per share, with a total value of $40,434,500.00. Following the transaction, the director now owns 48,433,261 shares in the company, valued at approximately $121,083,152.50. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 6.50% of the company's stock.

Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Stock News Headlines

27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
The Fed Can't Save Us This Time
The American economy is crumbling, and there's NOTHING Fed Chair Jerome Powell can do to stop it. Today, Dr. Martin Weiss reveals 7 simple steps you can take to protect your wealth from the biggest crisis of our lifetimes. Take action now before it's too late. pixel
7 Biotech Stocks With Key Catalysts for May
Lexicon Pharmaceuticals Q1 Earnings Preview
See More Headlines
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Company Calendar

Last Earnings
11/03/2021
Today
8/12/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CUSIP
52887210
Employees
87
Year Founded
1995

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+373.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-87,760,000.00
Net Margins
-88,803.67%
Pretax Margin
-88,803.67%

Debt

Sales & Book Value

Annual Sales
$300,000.00
Book Value
$0.39 per share

Miscellaneous

Free Float
171,690,000
Market Cap
$582.09 million
Optionable
Optionable
Beta
1.50

Social Links


Key Executives

  • Mr. Lonnel Coats (Age 57)
    CEO & Director
    Comp: $1.14M
  • Mr. Jeffrey L. Wade J.D. (Age 57)
    Pres & CFO
    Comp: $718.14k
  • Mr. Brian T. Crum (Age 49)
    Sr. VP, Gen. Counsel & Sec.
    Comp: $557.49k
  • Dr. Alan J. Main Ph.D. (Age 68)
    Exec. VP of Innovation & Chemical Sciences
    Comp: $574.2k
  • Dr. Craig B. Granowitz M.D. (Age 57)
    Ph.D., Sr. VP & Chief Medical Officer
    Comp: $450.46k
  • Dr. Robert J. Lefkowitz M.D. (Age 78)
    Consultant & Independent Director
    Comp: $50k
  • Ms. Kristen L. Alexander (Age 54)
    VP of Fin. & Accounting
  • Chas Schultz
    Exec. Director of Corp. Communications & Patient Advocacy
  • Ms. Wendy E. McDermott (Age 51)
    VP of HR
  • Dr. Kenneth B. Kassler-Taub M.D. (Age 66)
    Sr. VP of Regulatory Affairs & Quality Assurance













LXRX Stock - Frequently Asked Questions

Should I buy or sell Lexicon Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LXRX shares.
View LXRX analyst ratings
or view top-rated stocks.

What is Lexicon Pharmaceuticals' stock price forecast for 2022?

2 brokers have issued 12 month target prices for Lexicon Pharmaceuticals' stock. Their LXRX share price forecasts range from $10.00 to $20.00. On average, they anticipate the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 373.2% from the stock's current price.
View analysts price targets for LXRX
or view top-rated stocks among Wall Street analysts.

How have LXRX shares performed in 2022?

Lexicon Pharmaceuticals' stock was trading at $3.94 at the beginning of the year. Since then, LXRX stock has decreased by 19.5% and is now trading at $3.17.
View the best growth stocks for 2022 here
.

When is Lexicon Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our LXRX earnings forecast
.

How were Lexicon Pharmaceuticals' earnings last quarter?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The biopharmaceutical company earned $0.02 million during the quarter. Lexicon Pharmaceuticals had a negative trailing twelve-month return on equity of 93.58% and a negative net margin of 88,803.67%. During the same period last year, the business posted $0.71 EPS.

What is Lonnel Coats' approval rating as Lexicon Pharmaceuticals' CEO?

9 employees have rated Lexicon Pharmaceuticals Chief Executive Officer Lonnel Coats on Glassdoor.com. Lonnel Coats has an approval rating of 100% among the company's employees. This puts Lonnel Coats in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Lexicon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), ImmunoGen (IMGN), Geron (GERN), Micron Technology (MU), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Lexicon Pharmaceuticals' stock symbol?

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Who are Lexicon Pharmaceuticals' major shareholders?

Lexicon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (1.40%), Northern Trust Corp (0.37%), Integral Health Asset Management LLC (0.20%), Compagnie Lombard Odier SCmA (0.05%), Rhumbline Advisers (0.05%) and Credit Suisse AG (0.02%). Insiders that own company stock include Alexander A Santini, Christopher J Sobecki, International SCA Artal, James F Tessmer and Lonnel Coats.
View institutional ownership trends
.

How do I buy shares of Lexicon Pharmaceuticals?

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Lexicon Pharmaceuticals' stock price today?

One share of LXRX stock can currently be purchased for approximately $3.17.

How much money does Lexicon Pharmaceuticals make?

Lexicon Pharmaceuticals (NASDAQ:LXRX) has a market capitalization of $582.09 million and generates $300,000.00 in revenue each year. The biopharmaceutical company earns $-87,760,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

When was Lexicon Pharmaceuticals founded?

Lexicon Pharmaceuticals was founded in 1995.

How can I contact Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The official website for the company is www.lexpharma.com. The biopharmaceutical company can be reached via phone at (281) 863-3000, via email at cschultz@lexpharma.com, or via fax at 281-863-8010.

This page (NASDAQ:LXRX) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.